TORONTO, May 16, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the 'Company') (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the Company has cooperated with Canada's B.

多伦多，2024年5月16日/PRNewswire/--Visionary Holdings Inc.（以下简称“公司”）（纳斯达克：GV），一家拥有尖端人工智能和生命科学技术的私人教育提供商，在加拿大拥有子公司，在中国拥有市场合作伙伴，今天宣布该公司已与加拿大的B。

Braun Biochip Technology Group to establish Visionary Biotechnology Group Co., Ltd. in Toronto. Both economic value and social value will have an important impact. Visionary Group has a global impact in the field of biotechnology. Important value for short, medium and long term investors..

布劳恩生物芯片技术集团在多伦多成立远见卓识生物技术集团有限公司。经济价值和社会价值都将产生重要影响。远见集团在生物技术领域具有全球影响力。对短期、中期和长期投资者具有重要价值。。

Visionary Group has world-class biochip technology products to fill the vast market gap in Canada. B. Braun was founded in March 2011 at UBC University in Vancouver, Canada by Victor C.M. Leung, an academician of the Royal Canadian Academy of Sciences and the Academy of Engineering, and other Canadian academicians and American academician professors.

Visionary Group拥有世界一流的生物芯片技术产品，以填补加拿大巨大的市场空白。B、 2011年3月，加拿大皇家科学院和工程院院士Victor C.M.Leung以及其他加拿大院士和美国院士教授在加拿大温哥华的UBC大学成立了Braun。

B. Braun has invested nearly 150 million US dollars. After more than 10 years of focusing on the development of biochips, it has cooperated with the United States, and famous Canadian medical institutions have cooperated to develop a variety of products for medical bed testing, drug research and development, animal quarantine and cold chain transportation, including medical chips, animal chips, cold chain chips and agricultural chips.

B、 布劳恩已投资近1.5亿美元。经过十多年专注于生物芯片的开发，它与美国合作，加拿大著名医疗机构合作开发了多种用于医疗床检测、药物研发、动物检疫和冷链运输的产品，包括医疗芯片、动物芯片、冷链芯片和农业芯片。

Currently, the products have Complete clinical testing, process technology verification and small-scale production..

目前，产品已完成临床试验、工艺技术验证和小规模生产。。

The ability to realize applications in clinical testing, process validation and small-scale production demonstrates B. Braun's advantages and progress in this technical field. In addition, B. Braun cooperated with Ruikun Technology Group to build a factory in Nantong, China, with a total investment of US$300 million.

在临床测试、工艺验证和小规模生产中实现应用的能力证明了B.Braun在这一技术领域的优势和进步。此外，布劳恩与瑞坤科技集团合作，在中国南通建立工厂，总投资3亿美元。

This investment will not only help fill China's technological gaps in this field, but is also expected to bring up to 30 million US dollars in the next five years. The output value of more than 100 million US dollars will have an important impact on the economic value and social value of the B. Braun Group..

这项投资不仅有助于填补中国在这一领域的技术空白，而且预计在未来五年内将带来3000万美元。超过一亿美元的产值将对布劳恩集团的经济价值和社会价值产生重要影响。。

Visionary Group has cooperated with China's Zhejiang Ruikun Technology Group to build a factory in Nantong, China with a total investment of US$300 million to fill the gap in China's vast market. It is planned to be put into production in March 2025, with an output value of more than 3 billion US dollars in the next five years, creating huge economic and social value for the Vision Group..

远见卓识集团与中国浙江瑞坤科技集团合作，在中国南通建立工厂，总投资3亿美元，以填补中国广阔市场的空白。计划于2025年3月投产，未来五年产值将超过30亿美元，为愿景集团创造巨大的经济和社会价值。。

Innovative biochip technology demonstrates the company's world-class achievements in the field of biotechnology. Through long-term dedicated research and development of biochip technology and cooperation with famous medical institutions in North America, the company has successfully developed a variety of products that are used in many fields such as medical treatment, drug research and development, animal quarantine, and cold chain transportation..

创新的生物芯片技术展示了该公司在生物技术领域的世界级成就。通过长期专注于生物芯片技术的研发，并与北美著名医疗机构合作，公司已成功开发出多种产品，应用于医疗、药物研发、动物检疫、冷链运输等多个领域。。

Vision Biotechnology Group Co., Ltd.'s innovative biochip technology demonstrates the company's world-class achievements in the field of biotechnology. Through long-term dedicated research and development of biochip technology, the company has successfully developed a variety of products that are used in medical treatment, drug research and development, animal quarantine and cold chain transportation due to cooperation with medical institutions of the famous Canadian B.

Vision Biotechnology Group Co.，Ltd.的创新生物芯片技术展示了该公司在生物技术领域的世界级成就。通过长期专注于生物芯片技术的研发，公司与加拿大著名的B医疗机构合作，成功开发了多种用于医疗、药物研发、动物检疫和冷链运输的产品。

Braun Biochip Technology Group in North America. and many other fields..

北美洲的布劳恩生物芯片技术集团。和许多其他领域。。

Medical chips, animal chips, cold chain chips and agricultural chip products can be used in clinical testing, process verification and small-scale production, showing that Vision Biotechnology Group Co., Ltd.'s B. Braun Biochip Technology is the Top 1 market in this technology field. Advantage. In addition, B.

医疗芯片、动物芯片、冷链芯片和农业芯片产品可用于临床测试、工艺验证和小规模生产，可见Vision Biotechnology Group Co.，Ltd.的B.Braun生物芯片技术是该技术领域的第一大市场。优势。另外，B。

Braun Biochip Technology has cooperated with Ruikun Technology Group to build a factory in Nantong, China, with a total investment of US$300 million. This investment will not only help fill China's technology gap in this field, but is also expected to bring about With an output value of more than 3 billion US dollars, it will have an important impact on both the economic value and social value of Vision Biotechnology Group Co., Ltd..

博朗生物芯片科技与瑞坤科技集团合作，在中国南通建立工厂，总投资3亿美元。这项投资不仅有助于填补中国在这一领域的技术空白，而且预计将带来超过30亿美元的产值，这将对Vision Biotechnology Group Co.，Ltd.的经济价值和社会价值产生重要影响。。

Medical chip, animal chip, cold chain chip and agricultural chip technology innovation: The cooperation between Vision Group and B. Braun's biochip technology company represents the combination of global high-end manufacturing and biotechnology, which brings innovative solutions to key industries such as medical care.

医疗芯片、动物芯片、冷链芯片和农业芯片技术创新：Vision Group与B.Braun的生物芯片技术公司的合作代表了全球高端制造和生物技术的结合，为医疗保健等关键行业带来了创新解决方案。

plan..

计划。。

Leading the biochip market: Top 1 medical chips, animal chips, cold chain chips and agricultural chips fill the gaps in the Canadian and Chinese markets. B. Braun holds a leading position in the global biochip market.

引领生物芯片市场：排名第一的医疗芯片、动物芯片、冷链芯片和农业芯片填补了加拿大和中国市场的空白。B、 布劳恩在全球生物芯片市场上处于领先地位。

Cooperation and expansion: Vision Group's cooperation with internationally renowned institutions and the expansion of its global production base show its high growth potential and influence.

合作与扩张：愿景集团与国际知名机构的合作以及全球生产基地的扩张显示出其高增长潜力和影响力。

Global social contribution: Providing high-precision biochip products helps improve the health and welfare of humans and animals around the world.

全球社会贡献：提供高精度生物芯片产品有助于改善世界各地人类和动物的健康和福利。

High economic value: The expected output value of more than 3 billion US dollars in the next five years shows its huge market potential and economic benefits.

经济价值高：未来五年预计产值超过30亿美元，显示出巨大的市场潜力和经济效益。

Vision Group and B. Braun Group jointly established Vision Biotechnology Group Co., Ltd., which is moving towards becoming an important force in the global biochip industry and making significant contributions to global medical/health/new agricultural innovation technologies in all aspects of business and society..

Vision Group和B.Braun Group共同成立了Vision Biotechnology Group Co.，Ltd.，该公司正朝着成为全球生物芯片行业的重要力量的方向发展，并在商业和社会的各个方面为全球医疗/健康/农业新创新技术做出重大贡献。。

Biochips Market Size And Industry Analysis

生物芯片市场规模及行业分析

The global Biochips Market Size was valued at $12,005 million in 2021 and is projected to reach $25,568 million in 2028. The market is likely to grow with a high CAGR of 11.3% during the forecast period. The report presents comprehensive projections on the growth factors, opportunities, and restraining factors.

2021年，全球生物芯片市场规模为12.05亿美元，预计2028年将达到255.68亿美元。在预测期内，市场可能会以11.3%的高复合年增长率增长。该报告对增长因素、机会和制约因素进行了全面预测。

It also covers the geographical market along with comprehensive competitive landscape analysis..

它还涵盖了地理市场以及全面的竞争格局分析。。

Biochip Market: Overview

生物芯片市场：概述

Biochip is a biosecurity miniaturized medical device which helps in tracking accurate information. Additionally, it is massively used in molecular biology. These chips are capable of undergoing thousands of biological reactions in less time.

生物芯片是一种生物安全微型医疗设备，有助于跟踪准确的信息。此外，它被大量用于分子生物学。这些芯片能够在更短的时间内进行数千次生物反应。

COVID-19 Impact:

新型冠状病毒肺炎的影响：

The outbreak of the Covid-19 pandemic is likely to positively impact the growth of the global biochip market. Its growing applications align with the innovation of the Covid-19 vaccines and drugs, which in turn also contributes to the growth of the market during the pandemic. Its ability to find the gene sequences along with an array of biochemical constituents is likely to play an imperative role in fueling the adoption rate of biochips, particularly among the academic research space.

新型冠状病毒肺炎的爆发可能会对全球生物芯片市场的增长产生积极影响。其不断增长的应用与新型冠状病毒肺炎疫苗和药物的创新相一致，这反过来也有助于大流行期间市场的增长。它发现基因序列以及一系列生化成分的能力可能在推动生物芯片的采用率方面发挥着至关重要的作用，特别是在学术研究领域。

Among the Covid-19 pandemic, the biochip companies are looking forward to capitalizing on the opportunities in the current market landscape. The growing initiatives by the government and big private firms to develop novel solutions to fast track the development of the Covid-19 vaccines and drugs..

在新冠肺炎大流行中，生物芯片公司期待着利用当前市场格局中的机遇。政府和大型私人公司不断采取行动，开发新的解决方案，以快速开发新型冠状病毒疫苗和药物。。

Biochip Market: Growth Drivers

生物芯片市场：增长驱动因素

Growing usage of biochips in diverse areas will drive the growth of the global market.

生物芯片在不同领域的使用越来越多，这将推动全球市场的增长。

Biochip technologies are widely deployed across different areas, including microbiology, DNA analysis, clinical pathology, pharmacology, proctology, and biochemistry, among others. The ongoing research activities will fuel the usage of biochip technologies, particularly in the healthcare industry, which in turn will further expand the usage of biochips in the mainstream market in the forthcoming years.

生物芯片技术广泛应用于不同领域，包括微生物学，DNA分析，临床病理学，药理学，直肠学和生物化学等。正在进行的研究活动将推动生物芯片技术的使用，特别是在医疗保健行业，这反过来将进一步扩大生物芯片在未来几年主流市场的使用。

Biochip technology is also being used in sequence engineering, which is likely to augment the growth of the global biochip market and improve the performance & scalability of biochips solutions. Biochip manufacturers are emphasizing innovating distinct aspects of their miniature laboratory that can function properly with living organisms..

生物芯片技术也被用于序列工程，这可能会增加全球生物芯片市场的增长，并提高生物芯片解决方案的性能和可扩展性。生物芯片制造商正在强调创新微型实验室的不同方面，以使其能够与生物体正常工作。。

Biochips have also emerged as a crucial aspect to revolutionize DNA sequencing technology. Furthermore, it is likely to pave the way for advanced gene sequencing solutions. The combination of gene sequencing technology and biochip will address a number of biological tissues in the rare cell, single-cell, and red molecule analysis.

生物芯片也成为革新DNA测序技术的关键方面。此外，它可能为先进的基因测序解决方案铺平道路。基因测序技术和生物芯片的结合将解决稀有细胞，单细胞和红色分子分析中的许多生物组织。

However, biochip technology is growing continuously, and its throughput capacity is likely to expand the scope to diverse applications ranging from population-centric clinical studies to the detection of rare bacteria. Manufacturers are investing heavily in biochips for single-cell analysis. Investments are also likely to contribute towards the improvement of biochips and their versatile functions to enhance performance graphs exponentially..

然而，生物芯片技术正在不断发展，其吞吐量可能会将范围扩大到各种应用，从以人群为中心的临床研究到稀有细菌的检测。制造商正在大力投资用于单细胞分析的生物芯片。投资也可能有助于改进生物芯片及其多功能，以成倍提高性能图。。

Market dynamics

市场动态

Miniaturization of laboratory facilities can save time and cost, broad product portfolio offered by manufacturers and wide range of biochip applications are driving the growth of the biowafer market. Manufacturers provide technologically advanced products to minimize time and costs and enhance research outcomes.

实验室设施的小型化可以节省时间和成本，制造商提供的广泛产品组合和广泛的生物芯片应用正在推动生物晶片市场的增长。制造商提供技术先进的产品，以尽量减少时间和成本，提高研究成果。

For example, Micralyne, Inc. launched Silicon MicraFluidics technology in February 2018, a series of standardized microfluidic process technologies that enable rapid design and deployment of microfluidic-based products. Research and development to expand the scope of applications, and the advantages offered by biochip technology over traditional laboratories in terms of time, cost, and ease of use are expected to drive market growth..

例如，Micralyne，Inc.于2018年2月推出了硅微流体技术，这是一系列标准化的微流体工艺技术，可以快速设计和部署基于微流体的产品。扩大应用范围的研究和开发，以及生物芯片技术在时间、成本和易用性方面优于传统实验室的优势，预计将推动市场增长。。

About Visionary Holdings Inc.

关于Visionary Holdings Inc。

Visionary Holdings Inc. headquartered in Toronto, Canada, a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential.

Visionary Holdings Inc.总部位于加拿大多伦多，是一家私人教育提供商，拥有尖端的人工智能和生命科学技术，在加拿大设有子公司，在中国设有市场合作伙伴。该公司旨在通过技术创新为加拿大学生提供接受中学、大学、本科、研究生和职业教育的机会，使更多的人能够学习、成长并充分发挥其潜力。

As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at https://ir.visiongroupca.com/. .

作为加拿大教育项目和服务的全面整合提供商，该公司一直在并将继续为加拿大和国际学生提供服务。欲了解更多信息，请访问公司网站https://ir.visiongroupca.com/.。

Forward-Looking Statements

前瞻性声明

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs.

本公告中除历史事实声明外的所有声明均为前瞻性声明。这些前瞻性陈述涉及已知和未知的风险和不确定性，并基于公司目前对未来事件的预期和预测，公司认为这些事件可能会影响其财务状况、经营成果、业务战略和财务需求。

Investors can identify these forward-looking statements by words or phrases such as 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'would,' 'continue,' 'should,' 'may,' or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

投资者可以用“相信”、“期望”、“预期”、“估计”、“打算”、“会”、“继续”、“应该”、“可能”或类似的词语或短语来识别这些前瞻性陈述。公司没有义务公开更新或修改任何前瞻性声明，以反映随后发生的事件或情况，或其预期的变化，除非法律可能要求。

Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC..

虽然公司认为这些前瞻性声明中表达的预期是合理的，但不能向您保证这些预期会正确无误，公司提醒投资者，实际结果可能与预期结果存在重大差异，并鼓励投资者在公司注册声明和向美国证券交易委员会提交的其他文件中审查可能影响其未来结果的其他因素。。

For more information, please contact:

有关更多信息，请联系：

Visionary Holdings Inc.Investor Relations DepartmentEmail: ir@farvision.ca

Visionary Holdings Inc.投资者关系部电子邮件：ir@farvision.ca

SOURCE Visionary Holdings Inc.

SOURCE Visionary控股公司。